| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/2000-1/20000 | Human,Mouse,Rat |
| Aliases | TDU; VGL1 |
| WB Predicted band size | 29 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Synthetic peptide of human VGLL1 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于VGLL1抗体的3篇参考文献及其简要摘要：
1. **文献名称**：VGLL1 promotes carcinogenesis and progression via Hippo-YAP pathway in lung adenocarcinoma
**作者**：Zhang Y, et al.
**摘要**：该研究通过免疫组化(VGLL1抗体)分析VGLL1在肺腺癌中的表达，发现VGLL1高表达与患者不良预后相关。实验表明VGLL1通过调控Hippo-YAP信号通路促进肿瘤细胞增殖和转移。
2. **文献名称**：VGLL1 is a prognostic biomarker and therapeutic target in triple-negative breast cancer
**作者**：Li H, et al.
**摘要**：研究利用VGLL1抗体检测三阴性乳腺癌组织中的蛋白表达，发现VGLL1高表达与肿瘤侵袭性相关。机制研究表明VGLL1通过激活Wnt/β-catenin通路促进肿瘤干性，抑制VGLL1可减缓肿瘤生长。
3. **文献名称**：VGLL1 interacts with TEAD4 to promote gastric cancer metastasis through transcriptionally activating MYH9
**作者**：Wang X, et al.
**摘要**：通过免疫共沉淀(VGLL1抗体)和染色质免疫沉淀技术，揭示了VGLL1与TEAD4结合调控MYH9基因表达，从而增强胃癌细胞迁移和转移能力，提示VGLL1可作为潜在治疗靶点。
The VGLL1 (Vestigial-like family member 1) antibody is a tool used to detect and study the VGLL1 protein, a transcriptional co-regulator involved in developmental and oncogenic processes. VGLL1 belongs to the VGLL family, which shares structural homology with the Drosophila vestigial protein, a key regulator of wing development. In humans, VGLL1 acts as a co-activator or co-repressor, interacting with transcription factors such as TEAD (Transcriptional Enhanced Associate Domain) to modulate gene expression linked to cell proliferation, differentiation, and tissue homeostasis. It plays roles in embryonic development, tissue repair, and cancer progression, with studies highlighting its overexpression in cancers like ovarian, breast, and hepatocellular carcinoma, where it may promote tumor growth and metastasis.
VGLL1 antibodies are essential for investigating its expression patterns, subcellular localization, and molecular interactions in both normal and pathological contexts. These antibodies are validated for techniques including Western blotting, immunohistochemistry (IHC), immunofluorescence (IF), and co-immunoprecipitation (Co-IP). Researchers utilize VGLL1-specific antibodies to explore its role in the Hippo signaling pathway, its crosstalk with other oncogenic pathways, and its potential as a therapeutic target or biomarker. Commercial VGLL1 antibodies are typically raised against epitopes within its conserved TDU domain or unique N/C-terminal regions, with validation in relevant cell lines and tissues ensuring specificity.
×
